Skip to main content
Article thumbnail
Location of Repository

The Macrophage in Cystic Fibrosis

By Adam Wright


Background: Cystic fibrosis (CF) is caused by absent/defective CF transmembrane conductance regulator protein (CFTR). CF is characterized by thick airway mucus, chronic infection and neutrophil inflammation leading to respiratory failure. I analysed airway macrophages (MΦs) and their expression of pattern recognition receptors (PRRs) in CF, since these cells are crucial to airway immune defence and they can orchestrate inflammation. I also performed transcript analysis of CF monocyte-derived MΦs (MDMs).\ud Methods: Sputum was induced in CF paediatric and adult cohorts. Phenotype and function of CF MΦ were determined by flow cytometry and compared to controls. Monocytes (>92% purity) were grown in vitro to generate MDMs (n=15). Transcripts encoding the entire human genome were analysed (n=5) and expression of individual genes were confirmed by RT-PCR.\ud Results: In classical CF (n=10) there was an increase in the proportion of monocyte-like small MΦs (of total MΦ) compared to controls (n=10) (73 ± 18% and 16 ± 8%, respectively, p< 0.0001). In non-classical CF (n=4), with milder lung disease, small MΦs increased to 31 ± 20% (p>0.05). PRRs were absent on small MΦs from CF and control. In contrast, clear expression could be detected on large MΦs from control but not CF. In line with this, CF small MΦs showed a strongly reduced uptake of particles compared to controls. Microarray analysis of MDMs revealed α- and β-tryptase as being significantly higher under constitutive and stimulated conditions in CF compared to control. However, using RT-PCR, expression of α- and β-tryptase was similar between groups.\ud Conclusions: The phenotype of small MΦs in CF suggests that these cells are newly recruited monocytes from blood. Low expression of PRRs on these cells in CF and their reduced uptake indicates a reduced capacity to clear inhaled particles, which may contribute to further damage in CF. Further to this I was unable to confirm any transcript differences between CF and control MDMs due to mutant CFTR

Publisher: University of Leicester
Year: 2007
OAI identifier:

Suggested articles


  1. (2002). A component of innate immunity prevents bacterial biofilm development.&quot;
  2. (2006). A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.&quot;
  3. (1884). A disease of Daphnia caused by yeast. A contribution to the theory of phagocytes as agents for attack on disease-causing organisms.&quot; Archiv f patho logische Anatomie und Physiologie und f klinische medicin 96:
  4. (2006). A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation.&quot;
  5. (2006). A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms.&quot;
  6. (2002). A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator.&quot;
  7. (1993). A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples.&quot;
  8. (2004). A small molecule CFTR inhibitor produces cystic fibrosis-like submucosal gland fluid secretions in normal airways.&quot;
  9. (1953). Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas: clinical significance and relationship to the disease.&quot;
  10. (1999). Abnormal glutathione transport in cystic fibrosis airway epithelia.&quot;
  11. (2006). Abnormalities in the pulmonary innate immune system in cystic fibrosis.&quot;
  12. (2003). Absence of the macrophage mannose receptor in mice does not increase susceptibility to Pneumocystis carinii infection in vivo.&quot;
  13. (2001). Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition.&quot;
  14. (2007). Adenosine regulation of alveolar fluid clearance.&quot;
  15. (2004). Adhesion mechanisms regulating the migration of monocytes.&quot;
  16. (1991). Aerosol alpha I-antitrypsin treatment for cystic fibrosis.&quot;
  17. (2001). Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction.&quot;
  18. (2006). Airway surface liquid volume regulates ENaC by altering the serine protease-protease inhibitor balance: A mechanism for sodium hypersabsorption in cystic fibrosis.&quot;
  19. (1999). Altered respiratory epithelial cell cytokine production in cystic fibrosis.&quot;
  20. (2003). Alternative activation of macrophages. &quot;
  21. (1993). Alternative splicing of intron 23 of the human cystic fibrosis transmembrane conductance regulator gene resulting in a novel exon and transcript coding for a shortened intracytoplasmic C terminus.&quot;
  22. (2001). Alveolar JE/MCP-l and endotoxin synergize to provoke lung cytokine upregulation, sequential neutrophil and monocyte influx, and vascular leakage in mice.&quot;
  23. (1997). Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival.&quot;
  24. (2004). Alveolar macrophages in chronic obstructive pulmonary disease (COPD).&quot;
  25. (1991). Alveolar macrophages in idiopathic pulmonary fibrosis display a more monocyte-like immunophenotype and an increased release of free oxygen radicals.&quot;
  26. (2005). Alveolar macrophages regulate neutrophil recruitment in endotoxin-induced lung injury.&quot;
  27. (2005). An essential role for non-bone marrow-derived cells in control ofPseudomonas aeruginosa pneumonia.&quot;
  28. (2005). and 1. Savill
  29. (2006). Anti-inflammatory activity of immunoglobulin G resulting from Fe sialylation.&quot;
  30. (1992). Antibody responses to lipid A, core, and 0 sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients.&quot;
  31. (1994). Application of a flow cytometric method using autofluorescence and a tandem fluorescent dye to analyze human alveolar macrophage surface markers.&quot;
  32. (2005). Assembly of functional CFTR chloride channels.&quot; Annu Rev Physiol67:
  33. (2007). Association between pulmonary function and sputum biomarkers in cystic fibrosis.&quot;
  34. (2004). Association of cystic fibrosis with abnormalities in fatty acid metabolism.&quot;
  35. (1999). Association ofmannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis.&quot;
  36. (1986). Association with phagocytic inhibition of antiPseudomonas aeruginosa immunoglobulin G antibody subclass levels in serum from patients with cystic fibrosis.&quot;
  37. (1999). Augmented proliferation of human alveolar macrophagcs after allogeneic bone marrow transplantation.&quot;
  38. (1996). Bactericidal activity against Pseudomonas aeruginosa is acquired by cultured human monocyte-derived macrophages after uptake of myeloperoxidase.&quot;
  39. (1994). Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator.&quot;
  40. (1985). Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis.&quot;
  41. (1998). Biological activities and clinical application ofM-CSF.&quot;
  42. (2006). Biology of mast cell tryptase.&quot;
  43. (2003). Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease.&quot;
  44. (1992). Biphasic production ofIL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. Separation ofLPS- and cytokine-stimulated components using anti-tumor necrosis factor and anti-IL-l antibodies.&quot;
  45. (1998). Blood monocyte migration to acute lung inflammation involves both
  46. (2004). Bringing new treatments to the bedside in cystic fibrosis.&quot;
  47. (1989). Bronchial epithelial cells release chemoattractant activity for monocytes.&quot;
  48. (1994). Bronchoa1veolar lavage findings in cyst ic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation.&quot;
  49. (1995). Bronchoalveolar lavage cellularity in healthy children.&quot;
  50. (1997). cAMP and genistein stimulate HC03- conductance through CFTR in human airway epithelia.&quot;
  51. (2006). Carbohydrate-independent recognition of collagens by the macrophage mannose receptor.&quot;
  52. (2006). Carbon in airway macrophages and lung function in children.&quot;
  53. (1998). Catalase, myeloperoxidase and hydrogen peroxide in cystic fibrosis.&quot;
  54. (2007). CCSP regulates cross talk between secretory cells and both ciliated cells and macrophages of the conducting airway.&quot;
  55. (1990). CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.&quot;
  56. (2007). CD44 Regulates Macrophage Recruitment to the Lung in Lipopolysaccharide-Induced Airway Disease.&quot;
  57. (2005). Cdc42 and RhoB activation are required for mannose receptormediated phagocytosis by human alveolar macrophages.&quot;
  58. (2003). Cellular profiles of induced sputum in children with stable cystic fibrosis: comparison with BAL.&quot;
  59. (1989). Cellular versus Humoral Immunity: Determinants and Consequences of an Epic Nineteenth-Century Battle. A History of Immunology. London,
  60. (2005). CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains.&quot;
  61. (2006). CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis.&quot;
  62. (2002). CFTR is a monomer: biochemical and functional evidence.&quot;
  63. (2002). CFTR mutations and host susceptibility to Pseudomonas aeruginosa lung infection.&quot;
  64. (2006). CFTR regulates phagosome acidification in macrophages and alters bactericidal activity.&quot;
  65. (2005). CFTR: more than just a chloride channel.&quot;
  66. (1992). CFU-rAM, the origin of lung macrophages, and the macrophage lineage.&quot;
  67. (1998). Changes in sputum composition during sputum induction in healthy and asthmatic subjects.&quot;
  68. (1996). Chapter 8: References Seksek, 0., 1. Biwersi, et a1.
  69. (2004). Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model.&quot;
  70. (1991). Characterization of immune inducer and suppressor macrophages from the normal human lung.&quot;
  71. (2006). Characterization of myeloid and plasmacytoid dendritic cells in human lung.&quot;
  72. (1982). Characterization of the mannose/fucose receptor on human mononuclear phagocytes.&quot; 1 Reticuloendothel Soc
  73. (1992). Characterization of the murine macrophage mannose receptor: demonstration that the downregulation of receptor expression mediated by interferon-gamma occurs at the level of transcription. &quot;
  74. (2004). Characterization ofa population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers.&quot;
  75. (1990). Clearance of neutrophil-derived myeloperoxidase by the macrophage mannose receptor.&quot;
  76. (2007). Cleavage ofCXCRI on Neutrophils Disables Bacterial Killing in Cystic Fibrosis Lung Disease.&quot;
  77. (1995). Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages.&quot;
  78. (1987). Colony-stimulating factor-induced monocyte survival and differentiation into macrophages in serum-free cultures.&quot;
  79. (2007). Common and unique mechanisms regulate fibrosis in various fibroprolifcrati\'c diseases.&quot;
  80. (2000). Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD.&quot;
  81. (2002). Comparison of sputum induction using high-output and low-output ultrasonic nebulizers in normal subjects and patients with COPD.&quot;
  82. (1998). Comparison of the clinical manifestations of cystic fibrosis in black and white patients.&quot;
  83. (1986). Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity.&quot; Pediatr Res
  84. (1989). Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis.&quot;
  85. (1995). Complete map of cystic fibrosis mutation DF508 frequencies in Western Europe and correlation between mutation frequencies and incidence of disease.&quot;
  86. (2002). Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro.&quot;
  87. (2003). Cost of care and clinical condition in paediatric cystic fibrosis patients.&quot;
  88. (1997). Current understanding of the inflammatory process in cystic fibrosis: onset and etiology.&quot; Pediatr Pulmono124(2): 137-42: discussion 159-61.
  89. (2006). Cutting edge: novel human dendritic cell- and monocyte-attracting chemokine-like protein identified by fo ld reco gnition methods.&quot;
  90. (1996). Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.&quot;
  91. (1995). Cystic fibrosis lung inflammation: early, sustained, and severe.&quot;
  92. (2006). Cystic Fibrosis Mouse Models.&quot;
  93. (1981). Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay.&quot;
  94. (2007). Cystic Fibrosis Sputum Generates Chemotactic Collagen Fragments. American Thoracic Society,
  95. (1996). Cystic fibrosis transmembrane conductance regulator activation stimulates endosome fusion in vivo.&quot;
  96. (2000). Cystic fibrosis transmembrane conductance regulator does not affect neutrophil migration across cystic fibrosis airway epithelial monolayers.&quot;
  97. (1997). Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance ofPseudomonas aeruginosa from the lung.&quot; Proc Nat! Acad Sci
  98. (2005). Cystic fibrosis, disease severity, and a macrophage migration inhibitory factor polymorphism.&quot;
  99. (2005). Cystic fibrosis: terminology and diagnostic algorithms.&quot;
  100. (2005). Cystic fibrosis.&quot;
  101. (2000). Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. &quot;
  102. (2007). DAMPs, PAMPs and alarmins: all we need to know about danger.&quot;
  103. (2005). DC-SIGN induction in alveolar macrophages defines privileged target host cells for mycobacteria in patients with tuberculosis.&quot;
  104. (1997). Defective antigen presentation by lavage cells from terminal patients with cystic fibrosis.&quot;
  105. (2004). Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.&quot;
  106. (1999). Deficient hydrophilic lung surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis.&quot;
  107. (2000). Defmition of human blood monocytes.&quot;
  108. (2007). DeltaF508 mutation results in impaired gastric acid secretion.&quot; 1
  109. (2002). DeltaF508-CFTR causes constitutive NF-kappaB activation through an ER-overload response in cystic fibrosis lungs.&quot;
  110. (1996). Depletion of alveolar macrophagcs decreases neutrophil chemotaxis to Pseudomonas airspace infections.&quot;
  111. (1998). Descriptive Statistics. Practical Skills in Biomolecular Sciences.
  112. (1998). Destruction and loss of bronchial cartilage in cystic fibrosis.&quot;
  113. (2000). Differential chemokine receptor expression and function in human monocyte subpopulations.&quot;
  114. (2005). Differential cytokine profile in children with cystic fibrosis.&quot;
  115. (2007). Differential distribution of inflammatory cells in large and small airways in smokers.&quot;
  116. (2004). Differential expression of mast cell characteristics in human myeloid cell lines.&quot;
  117. (2007). Differential regulation of cytokine release and leukocyte migration by lipopolysaccharide-stimulated primary human lung alveolar type II epithelial cells and macrophages.&quot;
  118. (1995). Differential regulation of the mannose and SP-A receptors on macrophages.&quot;
  119. (2005). Differentiation to the CCR2+ Inflammatory Phenotype In Vivo Is a Constitutive, Time-Limited Property of Blood Monocytes and Is Independent of Local Inflammatory Mediators.&quot;
  120. (1976). Direct evidence for a bone marrow origin of the alveolar macrophage in man.&quot;
  121. (2005). Disparate regulation and function of the class A scavenger receptors SR-AI/II and MARCO.&quot;
  122. (2007). Distinct differentiation potential ofblood monocyte subsets in the lung.&quot;
  123. (2001). Distinct pattern of immune cell population in the lung of human fetuses with cystic fibrosis.&quot;
  124. (1999). Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease.&quot;
  125. (1964). Dithiothreitol, A New Protective Reagent For Sh Groups.&quot;
  126. (2004). Divergent roles for C-type lectins expressed by cells of the innate immune system.&quot;
  127. (2002). Early airway infection, inflammation, and lung function in cystic fibrosis.&quot;
  128. (1980). Early bacterial clearance from murine lungs. Speciesdependent phagocyte response.&quot;
  129. (1995). Early pulmonary inflammation in infants with cystic fibrosis.&quot;
  130. (1991). Effect of deleting the R domain on CFTR-gcncratcd chloride channels.&quot;
  131. (2006). Effective mucus clearance is essential for respiratory health.&quot;
  132. (1999). Effects of depletion of neutrophils or macrophages on development of cigarette smoke-induced emphysema.&quot;
  133. (2002). Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.&quot;
  134. (2004). Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines.&quot;
  135. (1993). Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4.&quot;
  136. (2002). Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis.&quot;
  137. (1995). Elastin and collagen degradation products in urine of patients with cystic fibrosis.&quot;
  138. (1983). Endocytosis and the recycling ofplasma membrane.&quot;
  139. (2004). Endogenous ligands of Toll-like receptors.&quot;
  140. (1990). Endothelial and leukocyte forms ofIL-8. Conversion by thrombin and interactions with neutrophils.&quot;
  141. (2002). Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis.&quot;
  142. (2005). Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils.&quot;
  143. (1994). Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis.&quot;
  144. (1998). Epithelial cell damage is induced by neutrophil-derived. not pseudomonas-derived, proteases in cystic fibrosis sputum.&quot;
  145. (2007). ER stress triggers apoptosis by activating BH3-only protein Bim.&quot;
  146. (1988). Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes.&quot;
  147. (1998). Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.&quot;
  148. (1978). Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages.&quot; Proc Nat! Acad Sci
  149. (2007). Exacerbations in cystic fibrosis. I: Epidemiology and pathogenesis.&quot;
  150. (1997). Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa.&quot;
  151. (1869). Experimentelle Beitrage zur Pneumonokoniosis-Lehre.&quot;
  152. (2002). Expression and functional characterization ofCFTR in mast cells.&quot;
  153. (1993). Expression and regulation of tumor necrosis factor in macrophages from cystic fibrosis patients.&quot;
  154. (1999). Expression of macrophage MARCO receptor induces formation of dendritic plasma membrane processes.&quot;
  155. (1994). Expression of the cystic fibrosis gene in adult human lung.&quot;
  156. (1991). Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin.&quot;
  157. (1993). Expression ofa mast cell tryptase in the human monocytic cell lines U-937 and Mono Mac 6.&quot;
  158. (2004). Expression profiling ofIL-10-regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-I 0 therapy.&quot;
  159. (2000). Extensive surface phenotyping of alveolar macrophages in interstitial lung disease.&quot;
  160. (2005). Ezekowitz
  161. (2000). Fibronectin-bound TNF-a1pha stimulates monocyte matrix metalloproteinase-9 expression and regulates chemotaxis.&quot;
  162. (2004). Fibrotic disease and the T(H) l/T(H)2 paradigm.&quot;
  163. (2005). Folding ofCFTR is predominantly cotranslational.&quot;
  164. (1988). Functional characterization of macrophage receptors for in vitro phagocytosis ofunopsonized Pseudomonas aeruginosa.&quot;
  165. (2006). Functional genomic responses to cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR(delta508) in the lung.&quot;
  166. (2001). Functional heterogeneity in liver and lung macrophages.&quot;
  167. (2002). Functional IL-l 0 deficiency in the lung of cystic fibrosis (cftr(-/-)) and IL-l 0 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages.&quot;
  168. (2004). Functional plasticity of macrophages: reversible adaptation to changing microenvironments.&quot;
  169. (2000). G551D cystic fibrosis mice exhibit abnormal regulation of inflammation in lungs and macrophages.&quot;
  170. (2001). G55lD CF mice display an abnormal host response and have impaired clearance of Pseudomonas lung disease.&quot;
  171. (1995). Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection.&quot;
  172. (2006). Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.&quot;
  173. (2002). Genetic deficiency ofhuman mast cell alpha-tryptase.&quot;
  174. (2005). Genetic modifiers of lung disease in cystic fibrosis.&quot;
  175. (1988). Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes.&quot;
  176. (1998). Glutathione permeability ofCFTR.&quot;
  177. (2001). GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1.&quot;
  178. (2003). HIF-1alpha is essential for myeloid cell-mediated inflammation.&quot;
  179. (1999). Histological and Histochemical Techniques: Theory and Practice.
  180. (2007). Hogaboam
  181. (2006). Hsp90 cochaperone Aha1 downregulation rescues misfolding ofCFTR in cystic fibrosis.&quot;
  182. (2005). Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5.&quot;
  183. (1992). Human airway macrophages. A technique for their retrieval and a descriptive comparison with alveolar macrophages.&quot;
  184. (2007). Human airway surface epithelial regeneration is delayed and abnormal in cystic fibrosis.&quot;
  185. (1986). Human alveolar lining material and antibacterial defenses.&quot;
  186. (1980). Human alveolar macrophages: effects of endotoxin in vitro.&quot;
  187. (1985). Human bronchoalveolar macrophage heterogeneity demonstrated by histochemistry, surface markers and phagocytosis.&quot;
  188. (1999). Human dendritic cells shed a functional, soluble form of the mannose receptor.&quot;
  189. (1997). Human monocyte-derived macrophages express an approximately 120-kD Ox-LDL binding protein with strong identity to CD68.&quot; Arterioscler Thromb Vase
  190. (2005). Human neutrophil elastase induces hypersecretion of mucin from well-differentiated human bronchial epithelial cells in vitro via a protein kinase C{delta}-mediated mechanism.&quot;
  191. (2006). Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands.&quot;
  192. (1989). Identification and characterization of a novel monocyte subpopulation in human peripheral blood.&quot;
  193. (1989). Identification of the cystic fibrosis gene: chromosome walking and jumping.&quot;
  194. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.&quot;
  195. (1989). Identification of the cystic fibrosis gene: genetic analysis.&quot;
  196. (1986). Identification of the macrophage mannose receptor as a 175-kDa membrane protein.&quot; Proc Nat! Acad Sci
  197. (2003). IL-10 controls Aspergillus fumigatus- and Pseudomonas aeruginosa-specific T-cell response in cystic fibrosis.&quot;
  198. (2007). IL-I0 induces IL-10 in primary human monocytederived macrophages via the transcription factor Stat3.&quot;
  199. (1990). Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis.&quot;
  200. (1986). Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide.&quot;
  201. (2005). Immunoregulatory functions of surfactant proteins.&quot;
  202. (2002). Impaired clearance ofapoptotic cells from cystic fibrosis airways.&quot;
  203. (2005). Impaired involution of mammary glands in the absence of milk fat globule EGF factor 8.&quot; Proc Nat! Acad Sci
  204. (1992). In vitro tumor necrosis factor-alpha secretion by monocytes from patients with cystic fibrosis.&quot;
  205. (2004). Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice.&quot;
  206. (1991). Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation ofneutrophils in lung fibrosis.&quot;
  207. (2002). Increased levels of the chemokines GROalpha and MCP-l in sputum samples from patients with COPD.&quot;
  208. (1991). Increased monocyte oxidase activity in cystic fibrosis heterozygotes and homozygotes.&quot;
  209. (1996). Indices of airway inflammation in induced sputum: reproducibility and validity ofcell and fluid-phase measurements.&quot;
  210. (2000). Induced sputum cell counts in healthy adults.&quot;
  211. (2000). Induced sputum cellularity. Reference values and distribution in normal volunteers.&quot;
  212. (1999). Induced sputum in patients with newly diagnosed sarcoidosis: comparison with bronchial wash and BAL.&quot;
  213. (2005). Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis.&quot;
  214. (2001). Induced Sputum: Whole Sample. Human Airway Inflammation: Sampling Techniques and Analytical
  215. (2001). Induced Sputum. Human Airway Inflammation:Sampling Techniques and Analytical
  216. (2006). Inducible NO synthase expression is low in airway epithelium from young children with cystic fibrosis.&quot;
  217. (2006). Induction of a homeostatic circuit in lung tissue by microbial compounds.&quot;
  218. (2000). Inflammation and infection in naive human cystic fibrosis airway grafts.&quot;
  219. (1999). Inflammation and repair processes in chronic obstructive pulmonary disease.&quot;
  220. (2002). Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis.&quot;
  221. (2006). Inflammatory cells in the airways in COPD.&quot;
  222. (1995). Inflammatory cytokines in cystic fibrosis lungs.&quot;
  223. (2006). Innate immune response in CF airway epithelia: hyperinflammatory?&quot;
  224. (2000). Innate immunity.&quot;
  225. (2004). Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered.&quot;
  226. (1993). Interleukin-8: an important chcmoattractant in sputum of patients with chronic inflammatory airway diseases.&quot;
  227. (1997). Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects.&quot;
  228. (1992). Isolation ofphenotypically and functionally distinct macrophage subpopulations from human bronchoalveolar lavage.&quot;
  229. (1989). KP 1: a new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections.&quot;
  230. (2005). Late diagnosis defmes a unique population of longterm survivors of cystic fibrosis.&quot;
  231. (1995). Leukocyte traffic in the lung.&quot; Annu Rev Physio157:
  232. (2000). Leukocyte trafficking in alveoli and airway passages.&quot;
  233. (1993). Leukotriene B4 markedly elevated in the epithelial lining fluid ofpatients with cystic fibrosis.&quot;
  234. (1992). Lipopolysaccharide-induced inhibition of scavenger receptor expression in human monocyte-macrophages is mediated through tumor necrosis factor-alpha.&quot;
  235. (1992). Localization of cystic fibrosis transmembrane conductance regulator mRNA in human fetal lung tissue by in situ hybridization.&quot;
  236. (2001). Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.&quot;
  237. (2004). Loss ofmicrobicidal activity and increased formation ofbiofilm due to decreased lactoferrin activity in patients with cystic fibrosis.&quot;
  238. (2002). Lung infections associated with cystic fibrosis.&quot;
  239. (2004). Lung inflammation as a therapeutic target in cystic fibrosis.&quot;
  240. (2007). Lung macrophages serve as obligatory intermediate between blood monocytes and alveolar macrophages.&quot;
  241. (1986). Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis.&quot;
  242. (2005). Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners.&quot;
  243. (1991). Macrophage Colony-Stimulating Factor Is Required for Human Monocyte Survival and Acts as a Cofactor for Their Terminal Differentiation to Macrophages In Vitro.&quot;
  244. (1989). Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages.&quot;
  245. (2007). Macrophages and the CC Chemokines MCP-1, MIPlalpha, MIP-l beta and MIP-3alpha Are Increased in the Lungs ofYoung Children with Cystic Fibrosis, Even in the Absence of Overt Infection. American Thoracic Society,
  246. (1990). Macrophages cultured in vitro release leukotriene B4 and neutrophil attractant/activation protein (interleukin 8) sequentially in response to stimulation with lipopolysaccharide and zymosan.&quot;
  247. (2005). Manifestations of cystic fibrosis diagnosed in adulthood.&quot;
  248. (2002). Mannose receptor-mediated regulation of serum glycoprotein homeostasis.&quot;
  249. (2004). MARCO expression on pediatric alveolar macrophages.&quot;
  250. (2006). MARCO mediates silica uptake and toxicity in alveolar macrophages from C57BL/6 mice.&quot;
  251. (2004). Mast cell tryptase, a still enigmatic enzyme.&quot;
  252. (1995). Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones.&quot;
  253. (2007). Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients.&quot;
  254. (2007). Matrix metalloproteinases and the regulation of tissue remodelling.&quot;
  255. (2003). Matrix metalloproteinases in lung repair.&quot;
  256. (1999). Matrix metalloproteinases. Matrix degradation and more.&quot;
  257. (1998). Mature monocytic cells enter tissues and engraft.&quot;
  258. (1999). MCP-l and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions.&quot;
  259. (2006). MHC class II proteins and disease: a structural perspective.&quot;
  260. (2005). MHC II molecules in inflammatory diseases: interplay of qualities and quantities.&quot;
  261. (2004). Microarray platforms--comparisons and contrasts.&quot;
  262. (2006). Microbiology of airway disease in a cohort of patients with cystic fibrosis.&quot;
  263. (1992). Milestones in cystic fibrosis.&quot;
  264. (2002). Molecular pathways of monocyte emigration into the alveolar air space of intact mice.&quot;
  265. (1988). Monoclonal antibody EBM/11: high cellular specificity for human macrophages.&quot;
  266. (1990). Monocyte adherence results in selective induction of novel genes sharing homology with mediators of inflammation and tissue repair.&quot;
  267. (2005). Monocyte and macrophage heterogeneity.&quot;
  268. (1989). Monocyte antigen CD 14 is a phospholipid anchored membrane protein.&quot;
  269. (2000). Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD.&quot;
  270. (2006). Monocyte emigration from bone marrow durinz bacterial infection requires signals mediated by chemokine receptor CCR2.&quot;
  271. (2000). Monocyte migration through the alveolar epithelial barrier: adhesion molecule mechanisms and impact of chemokines. &quot;
  272. (1988). Monocyte retention and migration in pulmonary inflammation. Requirement for neutrophils.&quot;
  273. (1992). Monocyte-selective transendothelial migration: dissection of the binding and transmigration phases by an in vitro assay.&quot;
  274. (2003). Monocytes are potent facilitators of alveolar neutrophil emigration during lung inflammation: role of the CCL2-CCR2 axis.&quot;
  275. (1990). Monocytes in cystic fibrosis: responsiveness to microbial stimuli.&quot;
  276. (2005). Monocytes recruited to the lungs ofrnice during immune inflammation ingest apoptotic cells poorly.&quot;
  277. (2004). MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions.&quot;
  278. (2007). MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation.&quot;
  279. (1995). Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients.&quot;
  280. (1987). Mucoid Pseudomonas aeruginosa resists nonopsonic phagocytosis by human neutrophils and macrophages.&quot;
  281. (2006). Mucus clearance and lung function in cystic fibrosis with hypertonic saline.&quot;
  282. (2002). Mucus clearance as a primary innate defense mechanism for mammalian airways.&quot;
  283. (1997). Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis.&quot;
  284. (2005). Nasal polyps in patients with and without cystic fibrosis: a differentiation by innate markers and inflammatory mediators.&quot;
  285. (2005). Negative regulatory role ofmannose receptors on human alveolar macrophage proinflammatory cytokine release in vitro.&quot;
  286. (1994). Neutrophil collagenase in sputum from patients with cystic fibrosis.&quot;
  287. (1990). Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CRI on neutrophils to create a functionally important opsonin receptor mismatch.&quot;
  288. (1992). Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. &quot;
  289. (2005). Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme.&quot;
  290. (2002). Neutrophil elastase induces mucin production by liganddependent epidermal growth factor receptor activation.&quot;
  291. (2003). Neutrophil recruitment and airway epithelial cell involvement in chronic cystic fibrosis lung disease.&quot;
  292. (2004). New concepts of the pathogenesis of cystic fibrosis lung disease.&quot;
  293. (2005). Nitric oxide-related products and myeloperoxidase in bronchoalveo1ar lavage fluids from patients with ALI activate NF -kappa B in alveolar cells and monocytes.&quot;
  294. (1993). No added benefit from nebulized amiloride in patients with cystic fibrosis.&quot;
  295. (2004). NO pathway in CF and non-CF children.&quot;
  296. (1994). Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis.&quot;
  297. (1995). Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-1 0, which is downregulated in cystic fibrosis.&quot;
  298. (2003). Normal host defense during systemic candidiasis in mannose receptor-deficient mice.&quot;
  299. (1979). Normal neutrophil and monocyte chemotaxis in patients with cystic fibrosis.&quot;
  300. (1875). On the pathology ofMiner's lung.&quot;
  301. (1970). Ontogeny of the haemopoietic system: yolk sac origin of in vivo and in vitro colony forming cells in the developing mouse embryo.&quot;
  302. (1971). Opsonic defect inpatients with cystic fibrosis of the pancreas.&quot; Proc Nat! Acad Sci
  303. (1984). Opsonin-independent phagocytosis of surface-adherent bacteria by human alveolar macrophages.&quot;
  304. (1979). Origin, Kinetics, and characteristics of pulmonary macrophages in the normal steady state.&quot;
  305. (1988). Oxidant-mediated inhibition of ligand uptake by the macrophage mannose receptor.&quot;
  306. (2006). Oxidants selectively reverse TGF-beta suppression ofproinflammatory mediator production.&quot;
  307. (2003). Pathophysiology and management of pulmonary infections in cystic fibrosis.&quot;
  308. (2004). Phagocytosis of apoptotic eosinophils but not neutrophils by bronchial epithelial cells.&quot;
  309. (1982). Phagocytosis ofPseudomonas aeruginosa by polymorphonuclear leukocytes and monocytes: effect of cystic fibrosis serum.&quot;
  310. (1989). Phenotype of blood monocytes and alveolar macrophages in interstitial lung disease.&quot;
  311. (1988). Phenotypic and functional changes in alveolar macrophages contribute to the pathogenesis of pulmonary sarcoidosis.&quot;
  312. (1999). Phenotypic and functional properties of dendritic cells isolated from human peripheral blood in comparison with mononuclear cells and T cells.&quot;
  313. (2000). Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome.&quot;
  314. (1997). Phosphorylation by protein kinase C is required for acute activation ofcystic fibrosis transmembrane conductance regulator by protein kinase A.&quot; 1
  315. (2005). Physiology and pathophysiology of proteinase-activated receptors (PARs): PARs in the respiratory system: cellular signaling and physiological/pathological roles.&quot;
  316. (2007). Pneumocystis-mediated IL-8 release by macrophages requires coexpression ofmannose receptors and TLR2.&quot;
  317. (2002). Points of control in inflammation.&quot;
  318. (2006). Polymorphisms ofTGF-betal in cystic fibrosis patients.&quot;
  319. (2003). Practical Flow Cytometry,
  320. (1993). Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis.&quot;
  321. (2001). Primary human alveolar epithelial cells can elicit the transendothelial migration ofCD14+ monocytes and CD3+ lymphocytes.&quot;
  322. (2002). Primary inflammation in human cystic fibros is small airways.&quot;
  323. (1990). Primary structure of the mannose receptor contains multiple motifs resembling carbohydrate-recognition domains.&quot;
  324. (1992). Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.&quot; Nature 358(63X9): 761-4. Chapter 8: References
  325. (1993). Proliferating alveolar macrophages in BAL and lung function changes in interstitial lung disease.&quot;
  326. (1974). Proliferative capacity of human alveolar macrophage.&quot;
  327. (1994). Properties and functions ofinterleukin-10.&quot; Adv Immuno156:
  328. (2001). Prostaglandins and leukotrienes: advances in eicosanoid biology.&quot;
  329. (1994). Protease-antiprotease imbalance in the lungs of children with cystic fibrosis.&quot;
  330. (2007). Protection against inhaled oxidants through scavenging of oxidized lipids by macrophage receptors MARCO and SR-AI/I1.&quot;
  331. (2004). Proteome comparison of alveolar macrophages with monocytes reveals distinct protein characteristics.&quot;
  332. (2005). Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects.&quot;
  333. (2002). Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.&quot;
  334. (2003). Pseudomonas aeruginosa elastase degrades surfactant proteins A and D.&quot;
  335. (2004). Pseudomonas aeruginosa flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells: implications for cystic fibrosis disease.&quot;
  336. (1993). Pseudomonas aeruginosa pili bind to asialoGMl which is increased on the surface of cystic fibrosis epithelial cells.&quot;
  337. (2005). Pseudomonas aeruginosa protease IV degrades surfactant proteins and inhibits surfactant host defense and biophysical functions.&quot;
  338. (1993). Pulmonary immune cells in health and disease: dendritic cells and Langerhans' cells.&quot;
  339. (1994). Pulmonary macrophages.&quot;
  340. (2005). Pulmonary surfactant protein A activates a phosphatidylinositol3-kinase/calcium signal transduction pathway in human macrophages: participation in the up-regulation ofmannose receptor activity.&quot;
  341. (2002). Pulmonary surfactant protein A up-regulates activity of the mannose receptor, a pattern recognition receptor expressed on human macrophages.&quot;
  342. (2006). Pulmonary T(H)2 response in Pseudomonas aeruginosainfected patients with cystic fibrosis.&quot;
  343. (1987). Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis.&quot;
  344. (1999). Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients.&quot;
  345. (1986). Quantitative aspects of lung pathology in cystic fibrosis.&quot;
  346. (2004). Quantitative cytokine gene expression in CF airway.&quot;
  347. (1973). Quantitative study on the production and kinetics of mononuclear phagocytes during an acute inflammatory reaction.&quot;
  348. (2003). Rapid recruitment of inflammatory monocytes is independent of neutrophil migration.&quot;
  349. (1984). Receptors for human IgG subclasses on human alveolar macrophages.&quot;
  350. (1996). Reduced IL-l 0 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembranre conductance regulator.&quot;
  351. (2005). Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces.&quot;
  352. (1994). Regional expression of CFTR in developing human respiratory tissues.&quot;
  353. (1999). Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo.&quot;
  354. (2004). Regulation of Antiprotease and Antimicrobial Protein Secretion by Airway Submucosal Gland Serous Cells.&quot;
  355. (1992). Regulation of plasma membrane recycling by CFTR.&quot;
  356. (2001). Regulation of the cystic fibrosis transmembrane conductance regulator Cl- channel by its R domain.&quot;
  357. (1991). Regulation oftransendothelial neutrophil migration by endogenous interleukin-8.&quot;
  358. (2004). Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD.&quot;
  359. (1997). Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice.&quot;
  360. (2006). Resident alveolar macrophages are replaced by recruited monocytes in response to endotoxin-induced lung inflammation.&quot;
  361. (1988). Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro.&quot;
  362. (2007). Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-l (IL-l) release and signaling through the IL-l receptor.&quot;
  363. (2002). Resolution of lung inflammation by CD44.&quot;
  364. (2003). Respiratory virus infections in cystic fibrosis.&quot;
  365. (1998). Role of alveolar macrophages in initiation and regulation of inflammation in Pseudomonas aeruginosa pneumonia.&quot;
  366. (2004). Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity.&quot;
  367. (1996). Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.&quot;
  368. (2002). Role of resident alveolar macrophages in leukocyte traffic into the alveolar air space of intact mice.&quot;
  369. (2006). Role of scavenger receptor MARCO in macrophage responses to CpG oligodeoxynucleotides.&quot;
  370. (2000). Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections.&quot;
  371. (1999). Role of the scavenger receptor MARCO in alveolar macrophage binding ofunopsonized environmental particles.&quot;
  372. (2005). Role ofIL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis.&quot;
  373. (2000). Role ofpulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa.&quot;
  374. (2003). Safety and use of sputum induction in children with cystic fibrosis.&quot;
  375. (2002). Safety of sputum induction.&quot;
  376. (2007). Scavenger receptor A dampens induction of inflammation in response to the fungal pathogen Pneumocystis carinii.&quot;
  377. (1987). Secretory products of macrophages.&quot;
  378. (1990). Selective down-regulation of alveolar macrophage oxidative response to opsonin-independent phagocytosis.&quot;
  379. (2006). Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications.&quot;
  380. (2000). Selective mobilization ofCDI4(+)CD16(+) monocytes by exercise.&quot;
  381. (2006). Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator.&quot;
  382. (2004). Seventeen-colour flow cytometry: unravelling the immune system.&quot;
  383. (2004). Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4.&quot;
  384. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.&quot;
  385. (2006). Specific aspects of flow cytometric analysis of cells from the lung.&quot; Exp Toxicol Patho157 Suppl2:
  386. (2004). Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2.&quot;
  387. (2005). Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.&quot;
  388. (2001). Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis.&quot;
  389. (2000). Sputum induction in young cystic fibrosis patients.&quot;
  390. (1969). Sputum liquefying agents: a comparative in vitro evaluation.&quot;
  391. (2006). Sputum MCP-l Concentration in Cystic Fibrosis.&quot;
  392. (1993). Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis.&quot;
  393. (2005). Structural changes to airway smooth muscle in cystic fibrosis.&quot;
  394. (2006). Structural model for the mannose receptor family uncovered by electron microscopy ofEndo180 and the mannose receptor.&quot;
  395. (1998). Structure of the human macrophage MARCO receptor and characterization of its bacteria-binding region.&quot;
  396. (1998). Subepithelial fibrosis and degradation of the bronchial extracellular matrix in cystic fibrosis.&quot;
  397. (2005). Submucosal gland dysfunction as a primary defect in cystic fibrosis.&quot;
  398. (2001). Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na(+)] and pH but elevated viscosity.&quot;
  399. (1992). Submucosal glands are the predominant site of CFTR expression in the human bronchus.&quot;
  400. (1993). Suppressive mechanisms of alveolar macrophages in interstitial lung diseases: role of soluble factors and cell-to-cell contact.&quot;
  401. (2001). Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis.&quot;
  402. (2004). Synergy between proinflammatory ligands ofG proteincoupled receptors in neutrophil activation and migration.&quot;
  403. (1994). T-cell and macrophage subsets in the bronchial wall of clinically healthy subjects.&quot;
  404. (2000). T-cell function and migration. Two sides of the same coin.&quot;
  405. (2006). The ABC protein turned chloride channel whose failure causes cystic fibrosis.&quot;
  406. (2003). The airway goblet cell.&quot;
  407. (2004). The alveolar macrophage: the forgotten cell in asthma.&quot;
  408. (2002). The biology of the macrophage.
  409. (2004). The class A macrophage scavenger receptor attenuates CXC chemokine production and the early infiltration of neutrophils in sterile peritonitis.&quot;
  410. (2005). The critical role ofhematopoietic cells in lipopolysaccharide-induced airway inflammation.&quot;
  411. (1992). The cystic fibrosis transmembrane regulator is present and functional in endosomes. Role as a determinant of endosomaI pH.&quot;
  412. (2002). The dendritic cell-specific adhesion receptor DCSIGN internalizes antigen for presentation to T cells.&quot;
  413. (2004). The development of early host response to Pseudomonas aeruginosa lung infection is critically dependent on myeloid differentiation factor 88 in mice.&quot;
  414. (1997). The diagnosis of cystic fibrosis.&quot;
  415. (1989). The distribution of phenotypically distinct macrophage subsets in the lungs ofpatients with cryptogenic fibrosing alveolitis.&quot;
  416. (2004). The evolution of airway function in early childhood following clinical diagnosis of cystic fibrosis.&quot;
  417. (2005). The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-gamma-mediated macrophage killing.&quot;
  418. (1999). The first-nucleotide binding domain of the cystic-fibrosis transmembrane conductance regulator is important for inhibition of the epithelial Na+ channel.&quot;
  419. (1995). The functional role of the ELR motif in CXC chemokine-mediated angiogenesis.&quot;
  420. (2000). The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type.&quot;
  421. (2000). The immune system. First of two parts.&quot;
  422. (1990). The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion.&quot;
  423. (2005). The inflammatory versus constitutive trafficking of mononuclear phagocytes into the alveo lar space of mice is associated with drastic changes in their gene expression profiles.&quot;
  424. (1996). The instructive role of innate immunity in the acquired immune response.&quot;
  425. (2004). The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus.&quot;
  426. The Molecular Genetic Epidemiology of Cystic Fibrosis.
  427. (1972). The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells.&quot;
  428. (2004). The multifaceted relationship between IL-l 0 and adaptive immunity: putting together the pieces of a puzzle.&quot;
  429. (1993). The phenotype of alveolar macrophages and its correlation with immune cells in bronchoalveolar lavage.&quot;
  430. (2004). The potential for Toll-like receptors to collaborate with other innate immune receptors.&quot;
  431. (1999). The potential of various lipopolysaccharides to release monocyte chemotactic activity from lung epithelial cells and fibroblasts.&quot;
  432. (1990). The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508).&quot;
  433. (2007). The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis.&quot;
  434. (2002). The role of inflammation in the pathophysiology ofCF lung disease.&quot; Clin Rev Allergy Immuno123(1):
  435. (2004). The role of matrix metalloproteinase 7 in innate immunity.&quot;
  436. (2004). The role of scavenger receptors in pathogen recognition and innate immunity.&quot;
  437. (2002). The role ofCC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice.&quot;
  438. (2007). The role ofCXC chemokines in pulmonary fibrosis.&quot;
  439. (2004). The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system.&quot;
  440. (2003). Therapeutic attenuation of pulmonary fibrosis via targeting ofIL-4- and IL-13-responsive cells.&quot;
  441. (1998). Thl and Th2 cytokines cooperate to stimulate mannosereceptor-mediated phagocytosis.&quot;
  442. (1994). Tissue-specific Fe gamma and complement receptor expression by alveolar macrophages determines relative importance of IgG and complement in promoting phagocytosis of Pseudomonas aeruginosa.&quot;
  443. (2005). TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells.&quot;
  444. (2005). TLR-induced inflammation in cystic fibrosis and noncystic fibrosis airway epithelial cells.&quot;
  445. (2003). TNF skews monocyte differentiation from macrophages to dendritic cells.&quot;
  446. (2004). Toll-like receptors in normal and cystic fibrosis airway epithelial cells.&quot;
  447. (2004). Toll-like receptors in the pathogenesis of human disease.&quot;
  448. (1993). Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs ofpatients with cystic fibrosis.&quot;
  449. (2004). Translational physiology: origin and phenotype of lung side population cells.&quot;
  450. (2003). Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC -1 cells. Mono-Mae6 cells, and human skin-derived mast cells.&quot;
  451. (1989). Tumor necrosis factor primes neutrophils for hypochlorous acid production.&quot;
  452. (2004). Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse.&quot;
  453. (1999). Two-colour flow-cytometric analysis ofpulmonary alveolar macrophages from smokers.&quot;
  454. (1980). Ultrastructure and function of alveolar macrophages from cystic fibrosis patients.&quot;
  455. (1997). Up-regulation ofIL-8 secretion by alveolar macrophages from patients with fibrosing alveolitis: a subpopulation analysis.&quot;
  456. (2005). Viral respiratory infections in cystic fibrosis.&quot;
  457. (2002). What does mucin have to do with lung disease?&quot;
  458. (2004). What is the incidence of cystic fibrosis in Italy? Data from the National Registry (1988-2001).&quot;

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.